FKD Therapies Oy

FKD Therapies Oy is a specialist gene therapy company based in Kuopio, Finland originally conceived by scientific and medical founders, Dr Nigel R Parker and Professor Seppo Yla-Herttuala,6 for the specific purpose of undertaking the development of adenovirus mediated interferon alfa-2b. FKD has led the overall development of nadofaragene firadenovec through manufacturing at FinVector Oy, late stage clinical trials and the current BLA filing. FinVector Oy and FKD Oy are part of the Trizell Group. *

	Start	2019-11-25 existent
	Group	Trizetto Group (Group)

	City	n. a. Kuopio
		Address record changed: 2019-11-27

Basic data	Employees	n. a.

		* Document for »About Section«: Ferring Pharmaceuticals S.A.. (11/25/19). "Press Release: Ferring and Blackstone Life Sciences Invest over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients". Saint-Prex & Cambridge, MA.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Trizetto Group (Group)

[1] Ferring Pharmaceuticals S.A.. (12/5/19). "Press Release: FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint". Washington, DC....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)